T0901317 (Standard)

T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα[1]. T0901317 activates FXR with an EC50 of 5 μM[2]. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively[3]. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice[4][5].

Product Specifications

CAS Number

[293754-55-9]

UNSPSC

12352005

Target

Apoptosis; FXR; LXR; Reference Standards; ROR

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Metabolic Disease; Cardiovascular Disease

Smiles

OC(C(F)(F)F)(C(F)(F)F)C1=CC=C(N(CC(F)(F)F)S(C2=CC=CC=C2)(=O)=O)C=C1

Molecular Formula

C17H12F9NO3S

Molecular Weight

481.33

References & Citations

[1]J R Schultz, et al. Role of LXRs in Control of Lipogenesis. Genes Dev. 2000 Nov 15;14 (22) :2831-8.|[2]Rough JJ, et al. Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res. 2010 May 26;3:13.|[3]Todd G Kirchgessner, et al. Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils. Cell Metab. 2016 Aug 9;24 (2) :223-33.|[4]Keith A Houck, et al. T0901317 Is a Dual LXR/FXR Agonist. Mol Genet Metab. Sep-Oct 2004;83 (1-2) :184-7.|[5]Naresh Kumar, et al. The Benzenesulfoamide T0901317 [N- (2,2,2-trifluoroethyl) -N-[4-[2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-Alpha/Gamma Inverse Agonist. Mol Pharmacol. 2010 Feb;77 (2) :228-36.|[6]Mingming Gao, et al. The Liver X Receptor Agonist T0901317 Protects Mice From High Fat Diet-Induced Obesity and Insulin Resistance. AAPS J. 2013 Jan;15 (1) :258-66.